523 related articles for article (PubMed ID: 19104004)
1. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.
Kushiro T; Mizuno K; Nakaya N; Ohashi Y; Tajima N; Teramoto T; Uchiyama S; Nakamura H;
Hypertension; 2009 Feb; 53(2):135-41. PubMed ID: 19104004
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study).
Mizuno K; Nakaya N; Ohashi Y; Tajima N; Kushiro T; Teramoto T; Uchiyama S; Nakamura H;
Circulation; 2008 Jan; 117(4):494-502. PubMed ID: 18172039
[TBL] [Abstract][Full Text] [Related]
3. The effect of low-dose pravastatin in metabolic syndrome for primary prevention of cardiovascular disease in Japan: a post hoc analysis of the MEGA study.
Matsushima T; Nakaya N; Mizuno K; Ohashi Y; Teramoto T; Yokoyama S; Ichikawa S; Ishikura N; Kamiyama K; Nakamura H;
J Cardiovasc Pharmacol Ther; 2012 Jun; 17(2):153-8. PubMed ID: 22573644
[TBL] [Abstract][Full Text] [Related]
4. Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: a post hoc analysis of the MEGA Study.
Nishiwaki M; Ikewaki K; Ayaori M; Mizuno K; Ohashi Y; Ohsuzu F; Ishikawa T; Nakamura H;
J Cardiol; 2013 Mar; 61(3):196-200. PubMed ID: 23265677
[TBL] [Abstract][Full Text] [Related]
5. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.
Nakamura H; Arakawa K; Itakura H; Kitabatake A; Goto Y; Toyota T; Nakaya N; Nishimoto S; Muranaka M; Yamamoto A; Mizuno K; Ohashi Y;
Lancet; 2006 Sep; 368(9542):1155-63. PubMed ID: 17011942
[TBL] [Abstract][Full Text] [Related]
6. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
[TBL] [Abstract][Full Text] [Related]
7. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
[TBL] [Abstract][Full Text] [Related]
8. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Hague W; Forder P; Simes J; Hunt D; Tonkin A;
Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
[TBL] [Abstract][Full Text] [Related]
9. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
N Engl J Med; 1998 Nov; 339(19):1349-57. PubMed ID: 9841303
[TBL] [Abstract][Full Text] [Related]
10. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin.
Nakamura H;
Atheroscler Suppl; 2007 Aug; 8(2):13-7. PubMed ID: 17586102
[TBL] [Abstract][Full Text] [Related]
11. Preventive effect of pravastatin on the development of hypertension in patients with hypercholesterolemia: A post-hoc analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.
Otsuka T; Mizuno K; Shinozaki T; Kachi Y; Nakamura H
J Clin Lipidol; 2017; 11(4):998-1006. PubMed ID: 28655522
[TBL] [Abstract][Full Text] [Related]
12. Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.
Tajima N; Kurata H; Nakaya N; Mizuno K; Ohashi Y; Kushiro T; Teramoto T; Uchiyama S; Nakamura H;
Atherosclerosis; 2008 Aug; 199(2):455-62. PubMed ID: 18635188
[TBL] [Abstract][Full Text] [Related]
13. The Combination of Elevated Triglycerides and Abnormal Fasting Glucose Increases Risk of Cerebral Infarction in Patients With Mild to Moderate Hypercholesterolemia: A Post Hoc Analysis of the MEGA Study.
Nakagami T; Nishimura R; Sone H; Tajima N
J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):169-73. PubMed ID: 24906541
[TBL] [Abstract][Full Text] [Related]
14. Pravastatin use and risk of coronary events and cerebral infarction in japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study.
J Atheroscler Thromb; 2000; 7(2):110-21. PubMed ID: 11426582
[TBL] [Abstract][Full Text] [Related]
15. Reduction in serum total cholesterol and risks of coronary events and cerebral infarction in Japanese men: the Kyushu Lipid Intervention Study.
Sasaki J; Arakawa K; Iwashita M; Matsushita Y; Kono S;
Circ J; 2003 Jun; 67(6):473-8. PubMed ID: 12808261
[TBL] [Abstract][Full Text] [Related]
16. Electrocardiographic events and cholesterol reduction with pravastatin in patients with hypercholesterolemia: the Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial.
Shimizu M; Koizumi J; Miyamoto S; Origasa H; Mabuchi H;
Int J Cardiol; 2005 Mar; 99(3):395-401. PubMed ID: 15771919
[TBL] [Abstract][Full Text] [Related]
17. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group
Circ J; 2004 Sep; 68(9):860-7. PubMed ID: 15329509
[TBL] [Abstract][Full Text] [Related]
18. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
[TBL] [Abstract][Full Text] [Related]
19. Prevention of mortality from coronary heart disease with pravastatin.
Tonkin AM; Ryan EW
Biomed Pharmacother; 1999 Oct; 53(9):405-8. PubMed ID: 10554675
[TBL] [Abstract][Full Text] [Related]
20. Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial (Holicos-PAT).
Koizumi J; Shimizu M; Miyamoto S; Origasa H; Mabuchi H
J Atheroscler Thromb; 2002; 9(5):251-9. PubMed ID: 12409635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
